Bio-Thera Solutions Ltd. has broadened its relationship with Russia’s Pharmapark while expanding the potential geographic reach of its proposed biosimilar to Janssen’s Stelara (ustekinumab), reaching license and supply agreements with Pharmapark for the Chinese player’s BAT2206 biosimilar ustekinumab candidate in Russia and other Commonwealth of International States countries.
Bio-Thera Strengthens Ties With Pharmapark By Adding Ustekinumab
Follows Earlier License And Supply Agreement For Golimumab Biosimilar
Deal-happy Bio-Thera Solutions has signed another license and supply agreement, agreeing to out-license its BAT2206 biosimilar ustekinumab candidate in Russia and other CIS countries to local player Pharmapark.
